Bioethics, Ltd.
BOTH · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.24 | -3.29 | 0.24 | 3.59 |
| FCF Yield | -8.76% | -1.64% | -8.69% | -1.27% |
| EV / EBITDA | -18.63 | 0.00 | -15.20 | -43.14 |
| Quality | ||||
| ROIC | 35.54% | 15.12% | 18.30% | 31.16% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.85 | 0.23 | 0.28 | 0.26 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -574.36% | 13.00% | 6.71% | 59.99% |
| Safety | ||||
| Net Debt / EBITDA | -4.65 | 0.00 | -8.93 | -6.67 |
| Interest Coverage | -2.27 | -1.08 | -1.03 | -1.24 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -140,671.97 |